新聞中心及演示文稿
上一篇文章   |   下一篇文章
創新平台, 監管信息公告 | 2015-08-19

Termination of Research & Development Alliance Agreement with Janssen Relating to HMPL-507 Project

London: Wednesday, 19 August 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that, Hutchison MediPharma Limited (“HMP”), its R&D subsidiary, has received notice from Janssen Pharmaceutical, Inc. (Janssen) of Janssen’s decision to terminate the Restated Research and Development Alliance Agreement dated 7 June 2010 (the “Agreement”) relating to HMPL-507 project.

The almost seven year alliance, which began in 2008, was amended in 2010 to refocus the target of the research on developing small molecule therapeutics against a specific novel molecular target in the area of inflammation/immunology. During this time, Janssen paid HMP an aggregate of approximately US$13 million in upfront and milestone payments and service fees and costs, which enabled both parties to generate substantial intellectual property, understanding and know-how relating to compounds in this designated area.

Janssen, at its sole discretion, has decided not to proceed with either HMPL-507 or any of the backup compounds developed under the Agreement.

The scientific view of HMP is that the specific molecular target represents a potential opportunity for targeted therapies in inflammation/immunology and possibly oncology and the compounds developed are of high quality and merit further development. HMP intends, in due course, and subject to final regulatory toxicity testing results, to independently commence clinical study.

HMP and Janssen will continue to work together on projects in other contexts.

Ends

 

Enquiries

 

Chi-Med Telephone: +852 2121 8200

Christian Hogg, CEO

 

Panmure Gordon (UK) Limited Telephone: +44 20 7886 2500

Richard Gray

Andrew Potts

 

Citigate Dewe Rogerson Telephone: +44 20 7638 9571

Anthony Carlisle Mobile: +44 7973 611 888

David Dible Mobile: +44 7967 566 919

About HMP

HMP is a novel drug R&D company focusing on discovering, developing and commercialising innovative therapeutics in oncology and autoimmune diseases. With a team of around 250 scientists and staff, its pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.

HMP is a subsidiary of Chi-Med. For more information, please visit: www.hmplglobal.com.

 

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK:0001). For more information, please visit: www.chi-med.com.